Consensus Lakefront Biotherapeutics NV

Stocks

LKFT

BE0003818359

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 16:55:00 15/07/2026 BST			5-day change	1st Jan Change
25.76 ^EUR	0.00%		-4.10%	-8.00%

07-13	Lakefront Biotherapeutics NV Announces Resignation of Paulo Fontoura as Director	CI
06-16	Lakefront Biotherapeutics NV commences an Equity Buyback for 10% of its issued share capital, under the authorization approved on April 28, 2026.	CI

Evolution of the Average Target: Lakefront Biotherapeutics NV

Evolution of the Target Price: Lakefront Biotherapeutics NV

Changes in Analyst Recommendations: Lakefront Biotherapeutics NV

21eeb48d3e5af3a6175.8p1Bu4Xqq-_z4pWYISrmJ9UkUewg0r8V82E7YhbGP8I.oMd07_OFw7XGpN3Odl6cXe1TFNsWhelhhi8LT3euaIaq0ybR2p_og8Kz5g~8ec37f805198b215a6fe05ab14a8a0e5

Analysts' recommendations: Lakefront Biotherapeutics NV

04-07	RBC Adjusts Price Target on Galapagos NV to $28 From $33, Maintains Sector Perform Rating	MT
02-25	RBC Capital Adjusts Galapagos NV PT to $33 From $32, Maintains Sector Perform Rating	MT
11-26	Bernstein Starts Galapagos at Market-perform, Says 'Unique in the Healthcare Space'	MT
11-07	RBC Adjusts Price Target on Galapagos to $32 From $28, Maintains Sector Perform Rating	MT
22/10/25	RBC Raises Price Target on Galapagos to $28 From $27, Keeps Sector Perform Rating	MT
25/04/25	RBC Cuts Price Target on Galapagos to $27 From $32, Keeps Sector Perform Rating	MT
14/02/25	Morgan Stanley Downgrades Galapagos to Underweight From Equal Weight, Adjusts Price Target to $22 From $31	MT
09/09/24	Leerink Partners Initiates Coverage on Galapagos NV With Market Perform Rating, $24 Price Target	MT
28/03/24	Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says	MT
28/03/24	BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41	MT
05/12/23	JPMorgan Cuts Galapagos Price Target to $37 From $45, Maintains Neutral Rating	MT
07/08/23	Morgan Stanley Adjusts Galapagos' Price Target to $40 From $42, Keeps Equalweight Rating	MT
07/08/23	RBC Cuts Price Target on Galapagos to $38 From $41, Keeps Sector Perform Rating	MT
31/05/23	JPMorgan Lowers Price Target on Galapagos to $45 From $52, Maintains Neutral Rating	MT
09/05/23	Morgan Stanley Adjusts Price Target on Galapagos to $42 From $44, Keeps Equalweight Rating	MT
08/05/23	Raymond James Upgrades Galapagos to Outperform From Market Perform, Price Target is $69	MT
08/05/23	RBC Cuts Price Target on Galapagos to $41 From $43 Amid 'Slowed Adoption' of Jyseleca, Maintains Sector Perform Rating	MT
27/02/23	Morgan Stanley Adjusts Price Target on Galapagos to $44 From $57, Maintains Equal-Weight Rating	MT
27/02/23	RBC Cuts Price Target on Galapagos to $43 From $53, Maintains Sector Perform Rating	MT
23/01/23	Jefferies Upgrades Galapagos to Hold From Underperform, Adjusts Price Target to $47.20 From $49	MT
07/11/22	RBC Lowers Price Target on Galapagos to $53 From $55, Keeps Sector Perform Rating	MT
13/10/22	Morgan Stanley Adjusts Galapagos' Price Target to $63 from $61, Keeps Equalweight Rating	MT
09/09/22	Morgan Stanley Downgrades Galapagos to Equalweight From Overweight, Cuts Price Target to $61 From $80	MT
15/08/22	Morgan Stanley Raises Galapagos NV's Price Target to $80 From $79, Maintains Overweight Rating	MT
08/08/22	RBC Cuts Price Target on Galapagos to $55 From $62, Maintains Sector Perform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LAKEFRONT BIOTHERAPEUTICS NV					+17.53%
	LONZA GROUP AG					+14.91%
	REVOLUTION MEDICINES, INC.					+8.27%
	IQVIA HOLDINGS INC.					+10.95%
	BEONE MEDICINES AG					+35.32%
	CELLTRION, INC.					+48.53%
	ASCENDIS PHARMA A/S					+13.4%
	MEDPACE HOLDINGS, INC.					-13.54%
	EUROFINS SCIENTIFIC SE					+2.94%
	ICON PUBLIC LIMITED COMPANY					+7.87%
	Average					+14.62%
	Weighted average by Cap.					+16.87%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

25.76EUR

Average target price

30.28EUR

Spread / Average Target

+17.53%

High Price Target

44.80EUR

Spread / Highest target

+73.91%

Low Price Target

19.00EUR

Spread / Lowest Target

-26.24%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Morgan Stanley
BofA Securities
JPMorgan Chase
Raymond James
Jefferies & Co.
Bryan, Garnier & Co.
Barclays
Deutsche Bank Securities
Citigroup
Maxim
Credit Suisse